bacampicillin and Pneumonia

Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Cefmenoxime; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia

Topics: Adult; Aged; Ampicillin; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Pneumonia; Respiratory Tract Infections; Sulbactam

Topics: Adolescent; Adult; Aged; Ampicillin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia

Bacampicillin (BAPC) is a esterified derivative of ampicillin (ABPC) developed recently by the Swedish company. In present investigation we measured the concentration of ABPC in plasma, lung and tracheobronchial tissues from normal, pleuritis and pneumonitis male albino rabbits after an oral administration of BAPC. In these 3 groups plasma level of ABPC reached the maximum at 30-50 minutes after oral administration, then showed a gradual decrease. The decaying curves of pleuritis and pneumonitis groups were steeper than that of control group. Plasma level of ABPC in pneumonitis group at the maximum value was about 1/2 comparing with that in control and pleuritis groups. ABPC levels of tracheobronchial tissues in pleuritis and pneumonitis groups were higher than that in control group at 60 minutes after oral administration of BAPC. On the other hand, tissue level of ABPC in control group was higher than that in pleuritis and pneumonitis groups at 120 minutes after oral administration of BAPC. ABPC level of lung tissues (L1 and L5) in control group was higher than that in pleuritis and pneumonitis groups at 60 minutes after oral administration of BAPC, on the other hand ABPC level of L3 in control group was lower than that in pleuritis and pneumonitis groups. ABPC levels of lung tissues (L1 - L5) at 120 minutes after oral administration of BAPC were higher in control group comparing with that in pleuritis and pneumonitis groups.

Topics: Administration, Oral; Ampicillin; Animals; Bronchi; Lung; Male; Pleurisy; Pneumonia; Rabbits; Tissue Distribution; Trachea

In an open multicentre study of bacampicillin (Penglobe), a new orally well absorb ed prodrug of ampicillin, 516 patients with acute exacerbations of chronic bronchitis or pneumonia were treated by a group of Belgian pneumologists or internists. Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. In patients with acute exacerbations of chronic bronchitis the clinical success rate was high, over 95% in both groups. An improvement in the sputum purulence score was seen in 93% of the patients with an initially purulent sputum and 69% had a normal mucoid sputum at follow-up. The clinical success rate in patients with pneumonia was also similar in both dosage groups with success rates over 96%. The total number of patients with adverse reactions was not more than 5-4%, of which the majority were considered mild or moderate. Each type of side-effect occurred in a frequency of 1-2% or less. There were no differences between the two dosage regiments as regards the frequency of side-effects indicates a remarkably good tolerance of bacampicillin also with the higher dosage.

Topics: Acute Disease; Adult; Aged; Ampicillin; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Pneumonia